134 related articles for article (PubMed ID: 16052255)
1. Vitreous leptin levels in retinal disease.
Maberley D; Cui JZ; Matsubara JA
Eye (Lond); 2006 Jul; 20(7):801-4. PubMed ID: 16052255
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
3. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy.
Yeh PT; Yang CM; Huang JS; Chien CT; Yang CH; Chiang YH; Shih YF
Ophthalmology; 2008 Apr; 115(4):734-737.e1. PubMed ID: 18177940
[TBL] [Abstract][Full Text] [Related]
4. Adrenomedullin and leptin levels in diabetic retinopathy and retinal diseases.
Er H; Doğanay S; Ozerol E; Yürekli M
Ophthalmologica; 2005; 219(2):107-11. PubMed ID: 15802936
[TBL] [Abstract][Full Text] [Related]
5. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
6. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
[TBL] [Abstract][Full Text] [Related]
7. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
8. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
[TBL] [Abstract][Full Text] [Related]
9. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Itakura H; Kishi S; Kotajima N; Murakami M
Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
[TBL] [Abstract][Full Text] [Related]
10. Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy.
Kauffmann DJ; van Meurs JC; Mertens DA; Peperkamp E; Master C; Gerritsen ME
Invest Ophthalmol Vis Sci; 1994 Mar; 35(3):900-6. PubMed ID: 8125753
[TBL] [Abstract][Full Text] [Related]
11. Vitreous levels of soluble vascular endothelial growth factor receptor (VEGFR)-1 in eyes with vitreoretinal diseases.
Asato R; Kita T; Kawahara S; Arita R; Mochizuki Y; Aiello LP; Ishibashi T
Br J Ophthalmol; 2011 Dec; 95(12):1745-8. PubMed ID: 21719570
[TBL] [Abstract][Full Text] [Related]
12. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
[TBL] [Abstract][Full Text] [Related]
13. Atrial natriuretic peptide in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy.
Rollin R; Mediero A; Martínez-Montero JC; Roldán-Pallarés M; Suárez-Leoz M; Vidal-Fernández P; Cortés-Valdés C; Fernández-Cruz A; Fernández-Durango R
Mol Vis; 2004 Jul; 10():450-7. PubMed ID: 15273657
[TBL] [Abstract][Full Text] [Related]
14. Increased osteopontin levels in the vitreous of patients with diabetic retinopathy.
Kase S; Yokoi M; Saito W; Furudate N; Ohgami K; Kitamura M; Kitaichi N; Yoshida K; Kase M; Ohno S; Uede T
Ophthalmic Res; 2007; 39(3):143-7. PubMed ID: 17505146
[TBL] [Abstract][Full Text] [Related]
15. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease.
Murugeswari P; Shukla D; Rajendran A; Kim R; Namperumalsamy P; Muthukkaruppan V
Retina; 2008 Jun; 28(6):817-24. PubMed ID: 18536597
[TBL] [Abstract][Full Text] [Related]
16. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.
Wang X; Wang G; Wang Y
Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381
[TBL] [Abstract][Full Text] [Related]
17. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy.
Capeans C; De Rojas MV; Lojo S; Salorio MS
Retina; 1998; 18(6):546-50. PubMed ID: 9869464
[TBL] [Abstract][Full Text] [Related]
18. Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease.
Spranger J; Meyer-Schwickerath R; Klein M; Schatz H; Pfeiffer A
Exp Clin Endocrinol Diabetes; 1999; 107(1):21-8. PubMed ID: 10077351
[TBL] [Abstract][Full Text] [Related]
19. Effect of retinal laser photocoagulation on the activity of metalloproteinases and the alpha(2)-macroglobulin proteolytic state in the vitreous of eyes with proliferative diabetic retinopathy.
Sánchez MC; Luna JD; Barcelona PF; Gramajo AL; Juarez PC; Riera CM; Chiabrando GA
Exp Eye Res; 2007 Nov; 85(5):644-50. PubMed ID: 17826767
[TBL] [Abstract][Full Text] [Related]
20. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion.
Noma H; Funatsu H; Mimura T; Harino S; Hori S
Ophthalmology; 2009 Jan; 116(1):87-93. PubMed ID: 19118700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
